Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1799 • ACR Convergence 2020
High Fat-Diet as a Catalyst to Lupus Development and Autoimmunity in MRL/lpr Mice
Hiba Ali¹, Juan Meng², Xuhua Shi², Linh Hellmers³, Swathi Dhulipala⁴, Patricia Kachur⁴, Therese Posas-Mendoza⁴, Robert Quinet⁵, William Davis⁵, Jerald Zakem⁴, Zongbing You² and Xin Zhang³, ¹Dept. of Rheumatology, Ochsner Medical Center, New Orleans, ²Tulane University Health Science Center, New Orleans, ³Institution of Translational Research, Ochsner Medical Center, New Orleans, ⁴Dept of Rheumatology, Ochsner Medical Center, New Orleans, ⁵Dept of Rheumatology, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with features of autoantibodies, skin rash, kidney and other multiple organ involvement. Evidence shows that obesity…
Abstract Number: 1817 • ACR Convergence 2020
Changes in Macular Capillary Network Measured with Optical Coherence Tomography-angiography in Patients with Systemic Lupus Erythematosus
Laura Pelegrin¹, Marc Figueras-Roca¹, Alvaro Olate-Perez¹, Javier Zarranz-Ventura¹, Ricardo Casaroli-Marano¹, Montse Morató¹, Vanesa Budi¹, José Ríos², Ricard Cervera³, Alfredo Adan¹ and Gerard Espinosa¹, ¹Hospital Clinic, Barcelona, Catalonia, Spain, ²Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain
Background/Purpose: Eye involvement in systemic lupus erythematosus (SLE) occurs in approximately one-third of patients, usually related to disease activity. An early diagnosis and treatment could…
Abstract Number: 1833 • ACR Convergence 2020
Hydroxychloroquine and Vitamin D Both Reduce Proteinuria in SLE
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Hydroxychloroquine (HCQ) and vitamin D are both immunomodulators in SLE, but work through different mechanisms. Hydroxychloroquine has been proven to triple renal response to…
Abstract Number: 1986 • ACR Convergence 2020
Determinants of Variation in Pediatric Systemic Lupus Erythematosus Care Delivery
Jon Burnham¹, Rosemary Peterson¹, Joy Ukaigwe¹, Lynsey Cecere¹, Andrea Knight² and Joyce Chang¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with pediatric systemic lupus erythematosus (pSLE) receive only a fraction of recommended care. Moreover, variation in care delivery likely contributes to pervasive racial…
Abstract Number: 0029 • ACR Convergence 2020
Urine Proteomic Classifiers Predict Renal Histological Activity and Chronicity Indices and May Predict Treatment Response in Lupus Nephritis
Emma Weeding¹, Andrea Fava¹, Jill Buyon², H. Michael Belmont³, Peter Izmirly⁴, Robert Clancy⁵, Jose Monroy-Trujillo⁶, Derek Fine⁶, William Apruzzese⁷, Harald Mischak⁸ and Michelle Petri⁹, ¹Johns Hopkins University, Baltimore, MD, ²Department of Medicine, NYU School of Medicine, New York, NY, ³NYU School of Medicine, New York, NY, ⁴Department of Medicine, New York University School of Medicine, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶Johns Hopkins University, Baltimore, ⁷., Boston, ⁸Multiple Institutions, Glasgow, United Kingdom, ⁹Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: Current management of lupus nephritis (LN) is guided by histopathological features on kidney biopsy and measurement of proteinuria. Urine proteomics is a non-invasive source…
Abstract Number: 0254 • ACR Convergence 2020
LLDAS (Low Lupus Disease Activity State) and Remission Prevent Damage Accrual in Systemic Lupus Erythematosus (SLE) Patients in a Primarily Mestizo Cohort
Manuel Ugarte-Gil¹, Rocío V. Gamboa-Cárdenas², Cristina Reátegui-Sokolova³, Victor Pimentel-Quiroz⁴, Mariela Medina², Claudia Elera-Fitzcarrald⁴, Francisco Zevallos², César A. Pastor-Asurza⁵, Jennifer Lofland⁶, Federico Zazzetti⁷, Chetan Karyekar⁸, Graciela Alarcón⁹ and Risto Perich-Campos⁵, ¹Department of Rheumatology, Hospital Nacional Guillermo Almenara Irigoyen. EsSalud; Universidad Científica del Sur, Lima, Peru, ²Department of Rheumatology. Hospital Nacional Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen; Universidad San Ignacio de Loyola, Lima, Peru, ⁴Department of Rheumatology. Hospital Nacional Guillermo Almenara Irigoyen. EsSalud; Universidad Científica del Sur, Lima, Peru, ⁵Department of Rheumatology. Hospital Nacional Guillermo Almenara Irigoyen. EsSalud; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Global Commercial Strategic Organisation, Johnson and Johnson, Horsham, PA, ⁷Janssen Scientific Affairs, LLC, Buenos Aires, Argentina, ⁸Janssen Global Services, LLC, Horsham, PA, ⁹Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama
Background/Purpose: LLDAS and remission have been proposed as treatment goals for SLE patients. However, their impact on damage prevention in patients from Latin America has…
Abstract Number: 0271 • ACR Convergence 2020
External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus
Alicia Malone¹, Alexandra Legge¹ and John Hanly¹, ¹Dalhousie University, Halifax, NS, Canada
Background/Purpose: Using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, a frailty index (FI) was recently developed as a measure of susceptibility…
Abstract Number: 0289 • ACR Convergence 2020
Endogenous Interferon-β and Low IL-4R on Transitional B Cells Promotes Lupus Nephritis
Fatima Alduraibi¹, Huma Fatima¹, W. Winn Chatham¹, Hui-Chen Hsu¹ and John Mountz², ¹University of Alabama at Birmingham, Birmingham, AL, ²University Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: We previously showed that B-cell endogenous interferon-beta (IFNβ) at the transitional (Tr) stage correlates with development of anti-Smith (anti-Sm) and renal disease as well…
Abstract Number: 0401 • ACR Convergence 2020
Prevalence and Characteristics of Systemic Sclerosis Patients Fulfilling the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus
Ronald Bass¹, Duncan Moore² and Virginia Steen², ¹Georgetown University School of Medicine, Washington, DC, ²Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC
Background/Purpose: Literature describing the overlap syndrome of SSc and SLE is limited and has employed a range of case definitions. Our study sought to use…
Abstract Number: 0527 • ACR Convergence 2020
Rituximab for Refractory Manifestations of the Antiphospholipid Syndrome: A Multicenter Israeli Experience
Nancy Agmon-Levin¹, Mark Berman², Liora Harel³, Merav Lidar⁴, Soad Hajyahia¹ and Daphna Paran⁵, ¹Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Scheider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel, Petach Tikva, Israel, ⁴Rheumatology unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Hod Hasharon, Israel, ⁵Department of Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: The clinical manifestations of the antiphospholipid syndrome (APS) are heterogeneous and related to anti-phospholipid antibodies (aPL). There is some evidence that B cells are…
Abstract Number: 0835 • ACR Convergence 2020
Pathogenic Effect of Chronic Stress-induced interleukin-12/23p40 on Neuropsychiatric System in Lupus-prone Mouse
Nobuya Abe¹, Kenji Oku¹, Yuichiro Fujieda¹, Nobuhiko Takahashi², Kohei Karino¹, Michihito Kono¹, Masaru Kato¹, Yuki Tanaka³, Rie Hasebe⁴, Olga Amengual¹, Miwako Yamasaki⁵, Masahiko Watanabe⁵, Masaaki Murakami³ and Tatsuya Atsumi⁶, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ²Division of Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ³Division of Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁴Biomedical Animal Research Laboratory, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁵Department of Anatomy, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan
Background/Purpose:Neuropsychiatric system is one of the major organs affected in systemic lupus erythematosus (SLE). However, the pathogenesis of neuropsychiatric SLE (NPSLE) has not been fully…
Abstract Number: 0855 • ACR Convergence 2020
Treatment of SLE with or Without Nephritis with the Immunoproteasome Inhibitor KZR-616: Updated Results of the MISSION Study
Richard Furie¹, Samir Parikh², Kenneth Harvey³, Christopher Kirk⁴, Darrin Bomba⁴ and MK Farmer⁵, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²The Ohio State University, Columbus, OH, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc, San Francisco, CA, ⁵Kezar, Raleigh, NC
Background/Purpose: Immunoproteasome inhibition has demonstrated meaningful therapeutic potential in preclinical models of systemic lupus erythematosus (SLE) and lupus nephritis (LN). KZR-616 is a first-in-class selective…
Abstract Number: 0887 • ACR Convergence 2020
Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network
Simon Helfgott¹, Jeremy Broestl², Kent Kwas Huston³, Deepali Rane², Jasvinder Singh⁴, Nehad Soloman⁵ and Colin Edgerton⁶, ¹BWH- HMS, Boston, MA, ²Trio Health, Louisville, CO, ³Kansas City Physician Partners, Kansas City, MO, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁶Articularis Healthcare, Summerville, SC
Background/Purpose: Systemic lupus erythematosus (SLE) treatments include steroids, antimalarials, immunosuppressants and/or biologics, though the use of biologics has been reported as minimal in claim-based studies…
Abstract Number: 0990 • ACR Convergence 2020
Interferon Lambda Promotes Human Plasma Cell Differentiation in Lupus and Healthy Donors
Jennifer Barnas¹, Jennifer Albrecht¹ and Jennifer Anolik¹, ¹University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by antinuclear autoantibodies produced by plasma cells. Type I interferon (IFN) are cytokines which…
Abstract Number: 1143 • ACR Convergence 2020
The Influence of YouTube on Spreading Awareness and Patient Education Regarding Systemic Lupus Erythematosus
Priyatha Garlapati¹, Jasmeen Uppal¹, Sarwat Umer² and Samina Hayat², ¹LSU Shreveport, Shreveport, ²LSU Shreveport, Shreveport, LA
Background/Purpose: A large global survey released by the World Lupus Federation showed that the awareness of SLE is low and many individuals have never heard…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].